/10 2002 On June 28, 2002, Chongqing Huali Holdings Co., Ltd. and the People's Government of Jishou City, Hunan Province signed the Agreement on the Acquisition and Merger of Jishou Pharmaceutical Factory in Hunan Province. Huali Holdings invested RMB 654.38+0 million to acquire its overall assets. Huali Group invested/kloc-0.70 billion yuan to acquire 29% equity of Kunming Pharmaceutical from Yunnan Pharmaceutical Group and hongta group, becoming the largest shareholder.

With the merger and acquisition strategy of Zhejiang Huali Group, the major shareholder, and the perseverance and tenacity of Wang Licheng, the chairman of Huali Group, Kunming Pharmaceutical has developed from a second-tier pharmaceutical company into a new force in the artemisinin market, and together with Huali Holdings, a subsidiary of Huali Group, it has mastered the fate of the global artemisinin market.

Zhejiang Huali Group:

Zhejiang Huali Technology Co., Ltd. is a private enterprise mainly engaged in system automation, informatization, product development, production, system integration and project implementation. On September 20 19/day, the list of the top 500 manufacturing enterprises in China was released, and Huali Group Co., Ltd. ranked 288th.

Zhejiang Huali Technology Co., Ltd. is a member of Huali Group, headquartered in Hangzhou High-tech Industrial Development Zone (national development zone), specializing in power system automation, informationization, product development, production, system integration, project implementation and technical services.